aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
NextCure, founded with a mission to revolutionize cancer treatment, is a biopharmaceutical company dedicated to discovering and developing next-generation immuno-oncology-based drugs. With a vision to become a global leader in novel immunomedicines, NextCure focuses on scientific innovation and addressing patient needs through its advanced therapeutic solutions. The company's primary market includes patients suffering from various forms of cancer, aiming to provide groundbreaking treatments that enhance the efficacy and safety of cancer care.
Notable figures associated with NextCure include key scientists and industry leaders who have significantly contributed to the field of immuno-oncology. The company has garnered attention and investment from prominent venture capital firms and strategic partners in the biopharmaceutical sector. Among its key achievements are the development of promising drug candidates currently undergoing clinical trials, demonstrating potential in improving patient outcomes. NextCure's impact lies in its commitment to transforming cancer treatment through cutting-edge research and innovative therapies, positioning itself as a significant player in the fight against cancer.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Cancer Drugs
Technology
Biotech
Tags
Biotech
Model Types
Financial, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was NextCure founded?
NextCure was founded in 2015.
Where is NextCure’s headquarters located?
NextCure’s headquarters is located in Beltsville, MD, US.
When was NextCure’s last funding round?
NextCure’s most recent funding round was for $150M (USD) in November 2019.
How many employees does NextCure have?
NextCure has 90 employees as of Feb 6, 2024.
How much has NextCure raised to-date?
As of July 05, 2023, NextCure has raised a total of $310M (USD) since Nov 12, 2019.
Add Comparison
Total Raised to Date
$310M
USD
Last Update Nov 12, 2019
Last Deal Details
$150M
USD
Nov 12, 2019
Post Ipo Equity
Total Employees Over Time
90
As of Feb 2024
NextCure Address
9000 Virginia Manor Road
suite 200
Beltsville,
Maryland
20705
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts